Uncertainty ahead for first OTC birth control pill
Reproductive health advocates have long argued that an over-the-counter birth control pill would increase access to contraception and decrease unwanted pregnancies.
Delivered every Tuesday and Friday by 12 p.m., Prescription Pulse examines the latest pharmaceutical news and policy.
Delivered every Tuesday and Friday by 12 p.m., Prescription Pulse examines the latest pharmaceutical news and policy.
By signing up you agree to allow POLITICO to collect your user information and use it to better recommend content to you, send you email newsletters or updates from POLITICO, and share insights based on aggregated user information. You further agree to our privacy policy and terms of service. You can unsubscribe at any time and can contact us here. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Reproductive health advocates have long argued that an over-the-counter birth control pill would increase access to contraception and decrease unwanted pregnancies.
The FDA’s advisory committees are tasked with providing the agency with outside scientific expertise on drugs or other medical products.
Leaders of the Senate Diabetes Caucus are pitching Senate Majority Leader Chuck Schumer as part of a larger drug pricing measure that could move forward as soon as this month.
Now CMS is expected to float a voluntary program that is limited to devices relevant to Medicare patients.
Vaccination uptake for Covid and the flu are subpar: About 20 percent of adults have received a bivalent booster and less than half of adults got a flu shot this year.
The Health Subcommittee will consider 17 bills and discussion drafts during its April 26 hearing that cover proposed measures.
The rise of new products in California doesn’t bode well for the FDA’s forthcoming rule, set to be finalized later this year.
Public comments on CMS’ implementation plan for its Medicare Drug Price Negotiation Program are due today.
While the Biden administration has already appealed to the 5th U.S. Circuit Court of Appeals, many fear it could set the nation down a path of unwinding FDA’s regulatory authority for other vital products.
That means the rush is on for committee staff to write the legislation with details still in flux, said the lobbyists, who were granted anonymity to discuss private committee deliberations.